OD's In America EBS has THE main stream Narcan that dominates the market. With increasing over doses though out America. Earnings could make this move like crazyyyyyyyy. If it is not this earnings then it is next, this stock can pop 50-100% in one day. Its a scalp trade. Longby LeapTradesUpdated 3
Short EBSA short at 3.03 to 2.54 with the necessary risk management will bring a 16.08% returnShortby KyleUK0
EBS- Quasimodo patternEBS- Quasimodo pattern -Key level support. -Demand zone. -Less supply volume.by phanvinhhai115
Emergent Biosolutions (EBS) - signs of potential breakout 4-hourEmergent Biosolutions (EBS) - signs of potential breakout Emergent Biosolutions (EBS): EBS is a clinical-stage biotechnology company developing a novel vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout. The stock is up over 20% in the past month, and it is trading above its 50-day and 200-day moving averages. Trend analysis for Emergent Biosolutions (EBS) for the past 30 days: Overall trend: Bullish: Despite a volatile November, EBS has shown a bullish overall trend for the past 30 days. The stock gained over 20%, rising from a low of $12.46 on November 4th to a high of $15.62 on December 2nd. Key events: Nov 9th: FDA advisory committee unanimously recommends approval of the company's supplemental new drug application (sNDA) for Narcan nasal spray to be available over-the-counter. Dec 2nd: Stock price rose 12.5% on this news, suggesting investor confidence in the potential for a positive FDA decision. Technical indicators: Moving averages: The 50-day moving average recently crossed above the 200-day moving average, indicating a bullish long-term trend. The stock is currently trading above both its 50-day and 200-day moving averages, further confirming the bullish trend. RSI: The RSI is currently at around 65, indicating that the stock is somewhat in the overbought territory. However, it doesn't necessarily spell a reversal, as other bullish indicators are present. Possible future scenarios: Bullish: If the FDA approves the sNDA for Narcan, this could lead to a significant increase in EBS's stock price. Neutral: If the FDA takes a long time to decide on the sNDA, this could lead to some volatility in the stock price. Bearish: If the FDA does not approve the sNDA, this could lead to a sharp decline in the stock price. Technical Analysis: Support: The stock has support at $12.00. Resistance: The stock has resistance at $15.00. Overall, the trend for Emergent Biosolutions (EBS) is bullish for the past 30 days, thanks to positive news events and technical indicators. However, investors should be aware of the potential for volatilities and future events that might affect the stock price.by day0Updated 2
Possible Pneumonia Stocks - signs of potential breakoutPossible Pneumonia Stocks - signs of potential breakout Emergent Biosolutions (EBS) : EBS is a clinical-stage biotechnology company developing a novel vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout . The stock is up over 20% in the past month , and it is trading above its 50-day and 200-day moving averages. Vaxart (VXRT) : Vaxart is a clinical-stage biotechnology company developing a tablet-based vaccine for pneumonia. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout . The stock is up over 30% in the past month , and it is trading above its 50-day moving average. Novavax (NVAX) : Novavax is a clinical-stage biotechnology company developing a vaccine for influenza. The company's stock has been undervalued for some time, but it is starting to show signs of a breakout . The stock is up over 40% in the past month , and it is trading above its 50-day and 200-day moving averages. Pfizer (PFE) : Pfizer is a large pharmaceutical company that develops and sells vaccines, including a vaccine for pneumonia. The company's stock is undervalued , and it is starting to show signs of a breakout . The stock is up over 10% in the past month , and it is trading above its 50-day moving average. Merck & Co. (MRK) : Merck is a large pharmaceutical company that develops and sells vaccines, including a vaccine for pneumonia. The company's stock is undervalued , and it is starting to show signs of a breakout . The stock is up over 8% in the past month , and it is trading above its 50-day moving average. These are just a few of the many stocks that may be undervalued and appear to be showing signs of potential breakout. It is important to do your own research before investing in any stock. Please share your ideas or charts in the comments below.by day0Updated 2215
EBS a biotech company focused on vaccinesEBS is a small biotechnology company whose forte is the clean processing and manufacturing facility that the FDA requires for certain bioprocessing to be certified for delivery of products to end-user patients. It is not a research facility like the one in China that accidentally released COVID and the global impact will be likely felt for another decade. EBS does depend on federal support and income from contract work from vaccine manufacturers. There is reasonable expectation or persistent and consistent revenues ongoing without fail unless the FDA decertified the facilities. On the chart, EBS is in a flat bottom triangle on its base. It is presently rising out of the triangle and towards the mean anchored VWAP It is just above The POC line which functions as dynamic support in the demand zone. I see a long trade with the stop loss below the POC line, the first target the blue line representing one standard deviation above the mean VWAP at about 9.4 while the second target is the redline two standard deviations above the mean VWAP at about 10.05 while the final target contemplates that EBS will challenge the high in May of 10.75. by AwesomeAvaniUpdated 3
$EBS - Narcan over the counter nose spray & Earnings 2/27I usually stray away from bio/biotech b/c of how volatile it is, but $EBS seems to be established with a $800M+ market cap, strong historicals, 20 PE ratio, and seems to be getting close to bottom. They also have an exciting narcan nasal spray product that can be sold over the counter they are working on releasing in 2023. Very relevant with all the overdoses going on in the US. What do you guys think? by ObiWanJacoby93113
$EBS levelsAdded some levels for EBS after 20% up side EBS got news on approval on nasal productby JoaoKunha0
EBS long 12.00-9.00$The price is approaching the strong level of $10.60, and there is already increased interest in this stock. This stock has been showing growth in December for many years, so it makes sense to consider buying in the $12.00-9.00 area, stop-loss at $8.5. The first target is $25, the second target is $35.Longby CDZV_trader2
Is EBS a buy as it hits a critical support level? EBS is currently hitting a critical support level around the 25 levels, which has been tested multiple times as key support and resistance level since 2009. I am planning on buying at this current level, with a very high-profit target and a tight 5% stop loss below the support level. The ATH is over 400% above the current price, so there's a lot of upside potential in this trade, but it will need to be managed carefully since the market is in a downtrend right now. Longby spiritualhealer117Updated 0
EBS: It's pretty bad when you underperform TNXPConsidering TNXP does... well... nothing, EBS underperforming TNXP is disappointing. Still holding and will continue to buy shares if SP falls back into the gray area at $25-$32. Monthly hammer + continuation off a high volume node + 2.618 fib should indicate a trend reversal. EBS was never a "squeeze" play because it's already worth a billion dollars. Additionally, I don't believe monkey pox is a serious pandemic regardless of what WHO says. EBS still has a pipeline of drugs that generates revenue and profit. With or without Monkey Pox, EBS should see $50-$60 (fibs) imo.Longby CrashWhenUpdated 0
EBS: FEAR THE MONKEYPOX!Apparently, there will be a WHO meeting next meeting concerning how serious Monkey Pox is going to be. Potential Long Term Head and Shoulders forming. $25 is a long term support level and Monthly VPOC. Speculative trade back to the 200W MA at $60Longby CrashWhenUpdated 774
EBS - Monkey pox is here Monkeypox has begun to expand. Vaccination is likely to increase in the coming months and this could lead to higher levels of shares of companies that produce vaccines.by StockBlog0
EBS - Head and Shoulders Pattern, Weekly1/1 line is a major Trend line Using the Fib circles the H&S pattern becomes more evident with the LS being rejected at the 1 level The H being formed at 1.618 and the RS being formed in the aftermath of the H formation I expect more downsides on this weekly timeframe until the strong support level is reached, which coincides also with the 1/2 Gann level by Bixley0
EBS ScalpJust broke trend, but long-term support below. I expect it to bounce and backtest the old trend, but no clue after. Could fall to $40 fib then maybe lower. I love this as a long at some point though. Company got bad press and missed a COVID vaccine delivery after a factory was shut down. It's open now though and they still have a huge backlog of business and 4 years of revenue growth.Longby competitiveDia367870
EBS LONGEBS broke the bear trend. Always when I saw such interception of MA lines, there was a huge growth. Now white candle (D) fixed above MA 50 and EMA 14, resistance broke. All point to growth. Longby MBAStocks1
EBS possible setup with 2 major supports EBS looks like a solid buy, I am investing at current price, if it goes down then I will add around second support. Reasons to buy: RSI looks oversold Stock trading at long term trendline 2021 consensus earning estimate 9.01 which means 7~ PE. Volume is increasing which shows it is getting attention Once the FDA will approve its facility, it will fly. Also, even if it breaks current level 2nd huge support level is not that far. So, doesn't have much to loose. Longby a4ankurbhutaniUpdated 2
$EBS Chart - Support, Resistance and TrendlineThree support and Three resistance drawn on daily chart. Trend reversal on daily chart. Need to look the chart again after one week Shortby catgovind0
EBSClassic Bullish divergence on both the 4hr and daily timeframe. Price has formed a descending wedge pattern and looks to have broken out. Support has been found at the 0.886 fibonacci retracement level which is also a historical daily resistance level before running to ATH.by Johnno-CenturionTradingUpdated 0
Pull Back Fishing Falling WedgeBullish engulfing candle today. The .886 fib level may have been the landing pad, but the bottom is not always the bottom. Biotech has been up and down so I am approaching this sector with caution for now. I have noted some biotech making daily or every other day yearly low and EBS made a new low yesterday and today although the 2 lows almost matched 58.79 today and 58.83 yesterday. Negative volume is high. Short interest is 7.2% Possible bullish divergence on RSI. No recommendationby lauralea4
Pull Back FishingAnother biotech. Does look like something gotta give soon. This stock is not afraid to gap down, so not for the faint of heart (o: EBS can gap up as well as it can gap down. Frequent gapping can indicate volatility. Not a recommendation. EBS pulled back on the 2nd leg a bit past the 0.618 fib level. If this were a Gartley pattern the landing pad would be the .786. While teaching yoga for many years, I have learned you have to be flexible (o: This one pulled back a bit below the 0.618, and possibly bottomed a bit above the 0.786. I am not sure the bottom is in yet though...maybe. Remains to be seen. Bullish falling wedge noted. Earnings 5-20 AMCby lauralea1
$EBS dipbullish buy at 98.21, conserv buy at 94.61; 102.23 target, stop loss 89.64; r/r 1.93by dilille010220
EMERGENT BIOSOLUTIONS Plan DailyHello traders, EMERGENT BIOSOLUTIONS is in a fake bearish push with a return of executed buy volume and a large hammer candle. Looking at the TIMEFRAME M1 we see a dash with a negotiated buy volume return, she came to the base of the bollinger to test it. And move up to the comfort zone to check it again. There is a great chance of breaking the price, with the momentum in the same moment the zone to slip on the next one and go on the high which follows. With three resistances to yield before a breakout of a comfort eon three on the TIMEFRAME H1 + filling a bearish breakout gap and six on the TIMEFRAME H1. Not enough force to test half of the intermediate median of ANDREWS PITCHFORK. Please LIKE & FOLLOW, thank you!Shortby stephanelibatd442